Get the Stockscreener App
17.03
3.36%
-0.6799
Anaptysbio Inc stock is traded at $17.03, with a volume of 113.69K.
It is down -3.36% in the last 24 hours and down -11.28% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$17.71
Open:
$17.65
24h Volume:
113.69K
Relative Volume:
0.12
Market Cap:
$547.71M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-2.801
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+4.36%
1M Performance:
-11.28%
6M Performance:
-57.56%
1Y Performance:
-30.68%
1-Day Range:
$16.98
$18.08
1-Week Range:
$15.78
$18.50
52-Week Range:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
16.99 | 547.71M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.17 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.01 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 - MarketBeat
Rhumbline Advisers Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
When (ANAB) Moves Investors should Listen - Stock Traders Daily
Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
AnaptysBio (ANAB) to Release Quarterly Earnings on Monday - MarketBeat
AnaptysBio: A Shadow Of Its Former Self (NASDAQ:ANAB) - Seeking Alpha
Palmoplantar Pustulosis Clinical and Non-Clinical Studies, - openPR
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at HC Wainwright - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - MarketBeat
H.C. Wainwright maintains AnaptysBio stock Neutral with $22 target By Investing.com - Investing.com Canada
Where AnaptysBio Stands With Analysts - Benzinga
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - Defense World
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates - MSN
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Large Growth in Short Interest - Defense World
AnaptysBio (NASDAQ:ANAB) Issues Earnings Results - MarketBeat
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20 - MarketBeat
AnaptysBio Reports Strong Progress in Clinical Trials - TipRanks
AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst - TipRanks
AnaptysBio reports Q4 EPS (72c), consensus ($1.70) - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 90c - StreetInsider.com
ANAPTYSBIO, INC SEC 10-K Report - TradingView
Anaptys Announces Participation in March Investor Conferences - The Manila Times
AnaptysBio's Rosnilimab Achieves Highest-Ever RA Treatment Response RateWhat Does This Mean for Investors? - StockTitan
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
(ANAB) Investment Analysis - Stock Traders Daily
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7%Here's What Happened - MarketBeat
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January - Defense World
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - MSN
What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings? - Armenian Reporter
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 16.5% After Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AnaptysBio Issued By HC Wainwright - Defense World
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given New $51.00 Price Target at Wells Fargo & Company - Armenian Reporter
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):